Does administration of prothrombin complex concentrates (PCCs) improve hemostasis in patients with factor Xa inhibitor-related intracranial hemorrhage?
PCCs demonstrate a high rate of hemostasis in factor Xa inhibitor-related intracranial hemorrhage, though randomized controlled trials are needed to confirm clinical efficacy.
Administration of PCCs after apixaban- and rivaroxaban-related ICH provided a high rate of excellent or good hemostasis (81.8%) coupled with a 3.8% thrombosis rate. Randomized, controlled trials evaluating the clinical efficacy of PCCs in patients with factor Xa inhibitor-related ICH are needed.
Panos et al. (2020) studied this question.